TheraRadar
Clinical-Stage Companies / EyePoint

EyePoint

Pre-Approval PRO BETA
18
Total Trials
10
Phase 3
6
Phase 2
5
Recruiting
211
Score

Pipeline by Phase

Phase 3
10
Phase 2
6
Phase 1
1

Therapeutic Focus

Diabetic Macular Edema Cataract DME Diabetic Macular Edema (DME) Wet Age Related Macular Degeneration

Clinical Trials (18)

NCT07449923 Phase 3 RECRUITING

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Started: 2/9/2026

NCT07449936 Phase 3 RECRUITING

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Started: 2/16/2026

NCT06668064 Phase 3 ACTIVE NOT RECRUITING

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

Started: 10/22/2024

NCT06683742 Phase 3 ACTIVE NOT RECRUITING

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

Started: 11/27/2024

NCT05550350 Phase 3 WITHDRAWN

A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery

Started: 9/1/2022

NCT05070728 Phase 3 TERMINATED

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert

Started: 10/13/2021

NCT05550363 Phase 3 WITHDRAWN

A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)

Started: 9/1/2022

NCT01694186 Phase 3 COMPLETED

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

Started: 8/2/2013

NCT02746991 Phase 3 COMPLETED

Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis

Started: 6/2/2015

NCT02748512 Phase 3 COMPLETED

Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis

Started: 2/23/2016

NCT05381948 Phase 2 COMPLETED

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

Started: 6/30/2022

NCT05383209 Phase 2 COMPLETED

Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

Started: 9/28/2022

NCT06099184 Phase 2 COMPLETED

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

Started: 1/15/2024

NCT03197870 Phase 2 COMPLETED

The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

Started: 6/9/2017

NCT04511650 Phase 2 TERMINATED

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

Started: 10/21/2020

NCT04405245 Phase 2 COMPLETED

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

Started: 6/6/2020

NCT04747197 Phase 1 COMPLETED

First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

Started: 1/20/2021

NCT05191706 Phase 4 RECRUITING

Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

Started: 1/4/2022

Drug Candidates

EYP-1901 Aflibercept (2.0 mg) Aflibercept 2mg/0.05mL Inj,Oph Dexycu Dexamethasone Prednisolone Acetate Ophthalmic Aflibercept 2Mg/0.05Ml Inj,Oph Sham Injector FAI Insert AKB-9778
Activity Status: Active
Last Trial Started: 2/16/2026
Last Trial Ended: 10/24/2024
Trials (12 months): 2
Completed Trials: 9
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.